Within life sciences, medical technology is among the sub-sectors that has seen plenty of deal activity this year and EY's Jeff Greene expects that to continue for the remainder of 2017.
In the first half of the year, "there's been a bigger mix of medical device deals than we normally would have expected to see," said Greene, EY's global transactions leader for life sciences, in a recent interview.
That's because the med tech sector is less affected by potential changes to the Affordable Care Act than people might be anticipating, he noted.
"Med tech M&A also continues to be driven by ongoing consolidation, improving equity prices and sufficient financial firepower to do deals," Greene said.
In April, Becton, Dickinson & Co. (BDX) said it was buying medical technology peer C.R. Bard Inc. (BCR) for $24 billion, the largest-ever deal for the 120-year-old acquirer. Bard primarily offers devices for vascular medicine, urology, oncology and surgery, while BD specializes in syringes and infusion products.
Also in April, Medtronic plc's (MDT) announced the sale of its patient care, deep vein thrombosis and nutritional insufficiency businesses to Cardinal Health Inc. (CAH) for $6.1 billion in cash. The businesses are part of the patient monitoring and recovery unit of Medtronic's minimally invasive therapies group.
Other transactions include Royal Philips NV (PHG) 's deal in June to acquire Spectranetics Corp. (SPNC) , a maker of devices used in minimally invasive procedures within the cardiovascular system, in a transaction that carries an enterprise value of around €1.9 billion.